Page 131 - Haematologica March 2020

Iron chelation in lower risk MDS patients
Table 2. Baseline characteristics for all matched subjects included in the propensity analyses
Co-variates
Age (years)
Sex
Female
Male
RBCT Intensity (per month) Cumulative RBCT units Ferritinlevel(μg/L,median,p25-p75) Comorbidity (MDSCI)
Low risk Intermediate risk High risk
Performance status
Unable to care for self
Unable to work
Able to work and normal activity
Prognostic indicator (IPSS-R)
Very low Low Intermediate High
Very high Ring-sideroblast present
Yes
No Plateletlevel(10x9/L,median,p25-p75) Hemoglobinlevel(g/dL,median,p25-p75) Quality of Life (EQ-5D)
Index(mean,SD)
VAS(mean,SD) Country
Austria
Croatia CzechRepublic Denmark
France Germany Greece
Israel
Italy theNetherlands Poland
Portugal
Romania RepublicofSerbia Spain
Sweden
UK
Overall Survival (OS) Unadjusted Adjusted****
Matched* data with imputations**
Non-chelated N = 591
Chelated N = 197
P
0.364
0.797
0.484 0.570 0.328 0.965
0.279
0.914
0.445
0.086 0.021
0.186
0.083 0.140
Standardized differences***
-0.077
-0.021
-0.058 -0.047 -0.086 -0.004
0.090
0.009
0.062
0.148 -0.194
0.125
0.165 -0.122
71 (11) 70
(9)
36.5%
63.5% (1.0) (4.7)
210 35.5%
381 64.5%
0.7 (1.0) 0.6 4.5 (4.9) 4.3
72
125
730.6 (494.6-977.3)
440 74.5% 145 24.5% 6 1.0%
4 0.7% 135 22.8% 452 76.5%
83 14.0% 337 57.0% 134 22.7% 34 5.8%
3 0.5%
419 70.9%
172 29.1% 162.5 (99.2-294) 8.8 (8.2-9.8)
0.7 (0.2)
64.8 (21.0)
25 4.2% 9 1.5% 58 9.8% 15 2.5% 113 19.1% 23 3.9% 80 13.5% 11 1.9% 11 1.9% 17 2.9% 22 3.7% 2 0.3% 34 5.8% 8 1.4% 11 1.9% 97 16.4% 55 9.3%
1.0
1.0
683.6 (504-915.5)
150 76.1% 42 21.3% 5 2.5%
1 0.5% 38 19.3% 158 80.2%
22 11.2% 120 60.9% 45 22.8%
9 4.6%
1 0.5%
134 68.0% 63 32.0% 224.0 (121-324) 8.4 (7.7-9.5)
0.7 (0.2)
68.1 (19.9)
10 5.1% 1 0.5% 25 12.7% 8 4.1% 40 20.3% 8 4.1% 23 11.7% 5 2.5% 5 2.5% 7 3.6% 8 4.1% 1 0.5% 11 5.6% 2 1.0% 5 2.5% 20 10.2% 18 9.1%
0.70 (0.51 – 0.95)
0.42 (0.27–0.63)
Continuous variables are reported as mean (Standard Deviation),while categorical variables are reported as number (%).*Matched by age,gender,country,red blood cell trans- fusion (RBCT) intensity,ferritin level,comorbidity,performance status,and Revised-International Prognostic Scoring System (IPSS-R) at eligibility.**Multiple imputations in RBCT intensity, ferritin level, comorbidity, Performance Status, and IPSS-R at eligibility for non-chelated patients. ***The standardized difference in percent is the mean difference as a percentage of the average standard deviation. ****Adjusted by age, sex, comorbidity, performance status, RBCT intensity, number of units transfused, IPSS-R, and RS present. MDSCI: myelodysplastic syndrome specific comorbidity index; EQ-5D: European Quality of Life - 5 dimensions.
haematologica | 2020; 105(3)
645